Mantle cell lymphoma of the iris treated by ibrutinib von Sales De Gauzy, T, Oberic, L, Fournié, P, Soler, V

Volltext

Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed von Sibaud, V., Brun, A., Meyer, N., Oberic, L., Lamant, L., Ysebaert, L.

Volltext

Molecular and clinical diversity in primary central nervous system lymphoma von Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., Alentorn, A.

Volltext

Tafasitamab lenalidomide in relapsed/refractory large B‐cell lymphomas: a multicentric real‐world French experience study von Paillassa, J., Degoutte, C., Oberic, L., Branche, N., Copin, M., Poullot, E., Laurent, C., Lacheretz, V., Haioun, C., Herbaux, C.

Volltext

Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA von Marouf, A., Chaubard, S., Michot, J., Liévin, R., Rossignol, J., Golfier, C., Allangba, O., Philippe, L., Tessoulin, B., Chauchet, A., Deau, B., Oberic, L., Vargaftig, J., Moignet, A., Clavert, A., Dulery, R., Brisou, G., Tardy, S., Fataccioli, V., Houot, R., Casasnovas, R., Thieblemont, C., Ghesquières, H., Carras, S., Le Gouill, S., Cartron, G., Marabelle, A., Tournilhac, O., Damaj, G., Gaulard, P., Leval, L., Lemonnier, F., Bachy, E., Hermine, O., Couronné, L., Jaccard, A.

Volltext

EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY von Delfau‐Larue, M., Viailly, P., Cartron, G., Morschhauser, F., Gros, F., Gastinne, T., Oberic, L., Bachy, E., Dulery, R., Feugier, P., Menard, C., Quelen, C., Pangault, C., Portugues, C., Gomes, L., Itti, E., Bailly, C., Lemonnier, F., Laurent, C., Houot, R.

Volltext

Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotin von Veleanu, L., Tesson, B., Lamant, L., Marçais, A., Bruneau, J., Kaltenbach, S., Brouzes, C., Degoutte, C., Moraly, J., Villarese, P., Lhermitte, L., Latiri, M., Hure, G., Chauchet, A., Delette, C., Grosleron, S., Toussaint, E., Cabrera, Q., Brice, P., Gros, F., Clavert, A., Oberic, L., Le Goff, M., Cereja, S., Meggetto, F., Macintyre, E., Asnafi, V., Sibon, D.

Volltext

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study von Lazarovici, Julien, Dartigues, Peggy, Brice, Pauline, Obéric, Lucie, Gaillard, Isabelle, Hunault-Berger, Mathilde, Broussais-Guillaumot, Florence, Gyan, Emmanuel, Bologna, Serge, Nicolas-Virelizier, Emmanuelle, Touati, Mohamed, Casasnovas, Olivier, Delarue, Richard, Orsini-Piocelle, Frédérique, Stamatoullas, Aspasia, Gabarre, Jean, Fornecker, Luc-Matthieu, Gastinne, Thomas, Peyrade, Fréderic, Roland, Virginie, Bachy, Emmanuel, André, Marc, Mounier, Nicolas, Fermé, Christophe

Volltext

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia von Bouvet, Emmanuelle, Borel, Cécile, Obéric, Lucie, Compaci, Gisèle, Cazin, Bruno, Michallet, Anne-Sophie, Laurent, Guy, Ysebaert, Loic

Volltext

Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia von Rossignol, J, Michallet, A-S, Oberic, L, Picard, M, Garon, A, Willekens, C, Dulery, R, Leleu, X, Cazin, B, Ysebaert, L

Volltext

AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY von Houot, R., Bachy, E., Cartron, G., Gros, F., Morschhauser, F., Oberic, L., Gastinne, T., Feugier, P., Dulery, R., Thieblemont, C., Joris, M., Jardin, F., Choquet, S., Casasnovas, O., Brisou, G., Cheminant, M., Bay, J., Gutierrez, F. Llamas, Menard, C., Tarte, K., Delfau, M., Itti, E., Bailly, C., Al Tabaa, Y., Laurent, C., Lemonnier, F.

Volltext

VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY von Sarkozy, C., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Damaj, G., Gastine, T., Ribrag, V., Casasnovas, O., Haioun, C., Houot, R., Jardin, F., Neste, E., Cheminant, M., Morschhauser, F., Callana, M., Ghesquieres, H., Gressin, R., Hermine, O., Le Gouill, S.

Volltext

Hepatitis E virus infection and ribavirin treatment in patients with chronic lymphocytic leukemia receiving ibrutinib von Protin, C, Abravanel, F, Laurent, G, Tavitian, S, Oberic, L, Izopet, J, Martin-Blondel, G, Ysebaert, L, Alric, L

Volltext

Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC von Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, Le Gouill, S

Volltext

LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL von Camus, V., Belot, Aurél., Oberic, L., Sibon, D., Ghesquières, H., Thieblemont, C., Fruchart, C., Casasnovas, O., Michot, Jean‐M., Molina, T. J., Bosly, A., Joubert, Clém., Haioun, C., Delarue, R., Tilly, H.

Volltext

HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY von Cheminant, M., Burroni, B., Le Bris, Y., Chartier, L., Oberic, L., Ribrag, V., Delfau, M.‐H., Thieblemont, C., Gressin, R., Canioni, D., Peyre, M., Laurent, C., Steimle, T., Kaltenbach, S., Asnafi, V., Macintyre, E., Callanan, M., Le Gouill, S., Hermine, O.

Volltext

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY von Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J. K., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., Jain, P., Calvo, R., Tao, L., Dlugosz‐Danecka, M.

Volltext

IBRUTINIB ABOVE 79 YEARS OLD FOR CHRONIC LYMPHOCYTIC LEUKEMIA: IMPORTANT TOXICITIES von Calleja, A., Branco, B., Teste, A., Bijou, F., Clavert, A., Brion, A., Laribi, K., Oberic, L., Guieze, R., Michallet, A., Ysebaert, L.

Volltext

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma von Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H, Friedberg, Jonathan W, Trněný, Marek, Sharman, Jeff P, Herbaux, Charles, Burke, John M, Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan M, Cheung, Matthew C, Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Flowers, Christopher R, Salles, Gilles

Volltext

Sarcoïdose secondaire aux inhibiteurs de BRAF : un évènement indésirable rare von Rouane, C., Dion, J., Sibaud, V., Oberic, L., Sukurdeep, G., comont, T.

Volltext